How do I buy Oruka Therapeutics, Inc. Common Stock (ORKA) stock?

Buying Oruka Therapeutics, Inc. Common Stock (ORKA) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "ORKA", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy ORKA by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if ORKA is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Oruka Therapeutics, Inc. Common Stock (ORKA) Stock

Q: What is the minimum investment for ORKA on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Oruka Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · ORKA

Trade ORKA

Key stats

Market cap: $7.27B
Price / Earnings ratio: -48539.2x
EPS (TTM): -$2.11
Volume: Loading
52-week high: $115.52
52-week low: $25.23

Source: third-party data provider, as of November 13, 2026

Compare with ORKA

Technical indicators

RSI 14: 67.76
MACD 12/26/9: 5.69
EMA 9 of MACD: 3.70
MACD histogram: 1.99
SMA 50: $89.12; Price above SMA 50
EMA 50: $91.29; Price above EMA 50
SMA 200: $71.95; Price above SMA 200
EMA 200: $69.91; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 4 analyst ratings

Strong Sell0

Sell0

Hold0

Buy4

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

0000

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

586M387M193M0

Revenue to Profit

2025

$0.0

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-105433.0

Net income

Earnings

No data available

Source: third-party data provider

About Oruka Therapeutics, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees68

CEODr. Lawrence Otto Klein Ph.D.

IPO DateAug 8, 1997

HeadquartersMenlo Park, CA

Key Executives

Name	Title	Year Born
Dr. Lawrence Otto Klein Ph.D.	President, CEO & Director	1983
Ms. Laura Sandler	Chief Operating Officer	1977
Mr. Paul T. Quinlan	General Counsel & Secretary	1963
Dr. Joana Goncalves M.D.	Chief Medical Officer	1974
Mr. Arjun Agarwal CPA	Senior VP of Finance & Treasurer	1976
Mr. Alan Lada	VP of IR & Capital Markets	—
Mr. Christopher Finch	Senior VP and Head of Business Development & Strategy	—
Dr. Rajiv Panwar	Senior VP and Head of Chemistry, Manufacturing & Controls	—
Mr. Larry Todd Edwards	Chief Commercial Officer	1963

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2024									-3.9	+13.1	-20.1	-7.5
2025	-32.6	-25.9	+3.5	+9.2	+8.6	-4.8	+15.2	+8.8	+23.6	+51.3	+14.9	+9.5
2026	+21.1	+0.3	+45.6	+35.7	-6.5	+73.0	+3.5	-2.3	-9.6	+16.1	+12.3

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Oruka Therapeutics, Inc. Common Stock (ORKA) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "ORKA", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy ORKA by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in Oruka Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Oruka Therapeutics, Inc. Common Stock (ORKA) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track ORKA's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Oruka Therapeutics, Inc. Common Stock (ORKA) Stock

Key stats

Compare with ORKA

Recent news

Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data

ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know

ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data

ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know

ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?

Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors

Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors

Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect?

Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect?

About Oruka Therapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Dividend

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade